

METHODS

Structure determination and refinement. The *T. thermophilus* RNAP holoenzyme was purified and crystallized as described previously²⁰. To obtain the complex crystals, the crystals of the apo-holoenzyme were transferred for 3 h into the drops containing collection buffer and 2 mM of dMyx⁴. The data were collected at beam line GM/CA-CAT (Advanced Photon Source, Argonne, USA). The crystals, although belonging to the same space group $P3_2$, had distinct unit cell parameters, $a = b = 235 \text{ \AA}$, $c = 255 \text{ \AA}$, as compared to the two previously studied *T. thermophilus* RNAP crystal forms; form I ($a = b = 236 \text{ \AA}$, $c = 250 \text{ \AA}$)^{20–22} and form II ($a = b = 240 \text{ \AA}$, $c = 253 \text{ \AA}$)^{23–25}. The data were processed using the HKL2000 data processing package (Supplementary Table 1)²⁶. As all previous holo-RNAP crystals, the crystals of the RNAP–dMyx complex were characterized by the perfect merohedral twinning coupled with the non-crystallographic symmetry²⁰. Refinement, therefore, was carried out using the twinning option of the CNS program (Supplementary Table 1)²⁷. The RNAP structure from the RNAP–Tgt complex (PDB accession 2BE5), from which the bridge helix ($\beta'1067$ – 1104) and the switch-2 segment ($\beta'602$ – 621) were omitted, was used as a starting model. Zonal scaling correction¹⁰ substantially improved the initial R_{free} and the quality of the electron density. The $|2F_{\text{obs}} - F_{\text{calc}}|$ electron density map calculated after the rigid body and B-factor refinement steps revealed the undistorted bridge helix (characteristic of the crystal form II, see earlier), straightening of the switch-2 α -helix and a very clear electron density for dMyx. However, the unfolded C-terminal portion of the switch-2 (residues $\beta'613$ – 619) structure was represented by a fragmentary electron density that allowed for alternative interpretations. After several trials, using the reduced level of the electron density ($\sim 0.8\sigma$, which was still above the noise) we were able to build a proper model that was characterized by a good, continuous electron density in the $|2F_{\text{obs}} - F_{\text{calc}}|$ electron density map for both the side- and main-chain atoms (note that all the previous partially wrong models did not improve the quality of the electron density in this region). After modelling of dMyx and switch-2 structures in the omit electron density, several rounds of the B-factor, positional, simulated annealing refinements and water 'pick' and water 'delete' procedures, alternating by manual model building using the program O²⁸ yielded a final R_{factor} of 24.0% and R_{free} of 27.0% for the RNAP–dMyx complex at 2.7 \AA resolution (Supplementary Table 1). The final model was of high quality as shown by the simulated annealing omit electron density map calculated for dMyx and the switch-2 motif (Supplementary Fig. 1). Structural figures were prepared using programs Molscript²⁹, Bobscript³⁰ and Raster3D³¹.

Isolation and assay of mutant *E. coli* RNAPs. Core wild-type and mutationally altered RNAPs were purified as described previously¹⁸ except that the ionic strength was maintained at or above 0.2 M at all chromatographic steps. Overexpression plasmids for β' R339A (pIA830), β E1279A (pIA870), β S1322E (pIA878), β' G336A (pIA880), β' F338A (pIA881), β' K345A (pIA882), β' Δ 333–335G (pIA883), β' K334A (pIA879) and β' R337A (pGB055) were constructed by site-directed mutagenesis and the sequenced fragments were recloned into pVS10-based vectors¹⁸. Holoenzymes were reconstituted with the twofold molar excess of σ^{70} . For steady-state abortive initiation assays, holo RNAP (20 nM) in 16 μl of 20 mM Tris-acetate, 20 mM sodium acetate, 2 mM magnesium acetate, 5% glycerol, 1 mM dithiothreitol (DTT), 0.1 mM EDTA, pH 7.9, 1 μM σ^{70} , were supplemented with desired concentration of dMyx (2 μl) and incubated for 15 min at 37 °C. Transcription was initiated by adding linear T7A1 promoter template (100 nM), ApU (200 μM), CTP (25 μM) and 3 μCi [$\alpha^{32}\text{P}$]-CTP (final reaction volume 20 μl). Reactions were allowed to proceed for 15 min at 37 °C and quenched by the addition of an equal volume of saturated urea in 90 mM Tris-borate, pH 8.3, 20 mM EDTA. Products were

analysed on 7 M urea, 12% (w/v) acrylamide:bisacrylamide (19:1) denaturing gels and RNA quantities were determined from Phosphorimager scans of the gels. dMyx IC₅₀ values for wild-type and variant RNAPs were determined by fitting concentration dependencies to hyperbolic function. The assay was repeated at least three times for each variant tested.

Footprinting analysis. A linear 153-bp DNA fragment containing λP_R promoter was made by PCR amplification using pIA226 (ref. 25) as a template with primers 17 (5'-CGTTAAATCTATCACCGCAAGGG) and 138 (5'-ATCGCCTGAAAGACTAGTCAGG). The top (non-template) DNA strand primer (number 17) was end-labelled with [³²P]- γ -ATP (Perkin Elmer) and polynucleotide kinase (Epicentre) and purified using G-50 spin columns (GE Healthcare). PCR products were gel-purified using a kit (Promega). Sequencing reactions were performed using the same labelled primer with a SequiTherm kit (Epicentre). For DNaseI protection experiments, wild-type holo *E. coli* RNAP (400 nM) was pre-incubated with 1 μM of Myx or an equal volume of 50% ethanol for 15 min at 37 °C in GBB buffer (20 mM Tris-HCl, 14 mM MgCl₂, 20 mM NaCl, 5% glycerol, 1 mM DTT, 0.1 mM EDTA, pH 7.9) supplemented with 1 mM CaCl₂. A labelled λP_R promoter fragment was added (at 20 nM) and the reaction was incubated for a further 10 min. Samples were shifted to room temperature (22 °C) and treated with 0.002 U of DNaseI (Roche, 10 U μl^{-1}) for 1 min. The reaction was stopped by the addition of an equal volume of buffer containing 15 mM EDTA and 8 M urea. For potassium permanganate probing, holo RNAP (400 nM) was pre-incubated with 1 μM of myxopyronin or an equal volume of 50% ethanol, 0.5% dimethylsulphoxide for 15 min at 37 °C in GBB buffer without reducing agents. Labelled λP_R promoter fragment was added (at 20 nM), and the reaction was incubated for a further 10 min. Samples were shifted to room temperature and treated with KMnO₄ at a final concentration of 10 mM for 60 s. The reaction was stopped by the addition of 5 \times stop buffer (1.5 M sodium acetate, pH 5.2, 80 mM EDTA, 6 M β -mercaptoethanol), samples were subjected to phenol-chloroform extraction and precipitated with ethanol. The pellet was dissolved in 20 μl of water and incubated with 100 μl of 0.5 M piperidine at 95 °C for 20 min. After another round of ethanol precipitation, DNA was dissolved on 96% formamide. Samples were heated at 95 °C for 3 min and analysed on 7 M urea, 8% (w/v) acrylamide:bisacrylamide (19:1) denaturing gels.

- Vassilyeva, M. N. *et al.* Purification, crystallization and initial crystallographic analysis of RNA polymerase holoenzyme from *Thermus thermophilus*. *Acta Crystallogr. D* **58**, 1497–1500 (2002).
- Artsimovitch, I. *et al.* Structural basis for transcription regulation by alarmone ppGpp. *Cell* **117**, 299–310 (2004).
- Vassilyev, D. G. *et al.* Crystal structure of a bacterial RNA polymerase holoenzyme at 2.6 \AA resolution. *Nature* **417**, 712–719 (2002).
- Artsimovitch, I. *et al.* Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. *Cell* **122**, 351–363 (2005).
- Temiakov, D. *et al.* Structural basis of transcription inhibition by antibiotic streptolydigin. *Mol. Cell* **19**, 655–666 (2005).
- Vassilyev, D. G. *et al.* Structural basis for transcription inhibition by tagetitoxin. *Nature Struct. Mol. Biol.* **12**, 1086–1093 (2005).
- Otwinowski, Z. & Minor, W. Processing X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* **276**, 307–326 (1997).
- Brunger, A. T. *et al.* Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr. D* **54**, 905–921 (1998).
- Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A* **47**, 110–119 (1991).
- Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. *J. Appl. Crystallogr.* **24**, 946–950 (1991).
- Esnouf, R. M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. *Acta Crystallogr. D* **55**, 938–940 (1999).
- Merritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. *Methods Enzymol.* **277**, 505–524 (1997).